Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.67 |
| ▸ | BRAF | P15056 | 15/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.67 |
| ▸ | TNNI3K | Q59H18 | 14/20 | 0.67 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972391 | 0.90 | KDR (0.66) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL12972405 | 0.90 | KDR (0.56) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL12972259 | 0.87 | KDR (0.62) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL11966512 | 0.87 | KDR (0.57) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL2778523 | 0.87 | RIPK1 (0.54) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL12972413 | 0.86 | RIPK1 (0.52) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL2777935 | 0.85 | RIPK1 (0.53) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL2778840 | 0.85 | KDR (0.62) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL11966503 | 0.85 | KDR (0.66) | KDRBRAFMAPK14TNNI3KRIPK1 | |
| SCHEMBL11966506 | 0.85 | KDR (0.57) | KDRBRAFMAPK14TNNI3KRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885BRAF 3/4885MAPK14 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.